HiRO and Differentia Biotech Sign MOU for AI Clinical Trial Simulation

Aug 28, 2026
HiRO and Differentia Biotech signed an MOU to collaborate on AI powered clinical trial simulation models that combine clinical operations data with digital twin and modeling platforms.

HiRO and Differentia Biotech signed a Memorandum of Understanding to collaborate on AI powered clinical trial simulation, the companies announced in a press release. The agreement was formalized at HiRO's office and covers joint work on simulation models and related commercial offerings for biopharmaceutical sponsors.

The collaboration will combine HiRO's clinical operations, data science, and real world data work with Differentia Biotech's digital twin, modeling, and simulation platforms. The companies said the models will focus on trial design, patient selection, subject number planning, and earlier sponsor decision making.

HiRO said the work will apply across complex areas including oncology, rare disease, cell and gene therapy, and radiopharmaceuticals. The companies said they expect to share more details on specific initiatives as the partnership progresses.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.